Detection of KRAS mutations in circulating tumour DNA from plasma and urine of patients with colorectal cancer
R Ohta, T Yamada, H Sonoda, A Matsuda… - European Journal of …, 2021 - Elsevier
Abstract Background Circulating tumour DNA (ctDNA) is very useful for purposes of cancer
genetics; however, it has some limitations. Recently, ctDNA in body fluids, such as urine,
sputum, and pleural effusion, has been investigated. The aim of this study was to evaluate
the quantity of ctDNA derived from urine (trans-renal ctDNA) and the accuracy of KRAS
mutation detection in relation to disease stage in colorectal cancer. Methods Urine, plasma,
and tissue samples were collected from consecutively resected colorectal cancer patients …
genetics; however, it has some limitations. Recently, ctDNA in body fluids, such as urine,
sputum, and pleural effusion, has been investigated. The aim of this study was to evaluate
the quantity of ctDNA derived from urine (trans-renal ctDNA) and the accuracy of KRAS
mutation detection in relation to disease stage in colorectal cancer. Methods Urine, plasma,
and tissue samples were collected from consecutively resected colorectal cancer patients …